Breast Cancer Research (May 2024)
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
- Samuel A. Jacobs,
- Ying Wang,
- Jame Abraham,
- Huichen Feng,
- Alberto J. Montero,
- Corey Lipchik,
- Melanie Finnigan,
- Rachel C. Jankowitz,
- Mohamad A. Salkeni,
- Sai K. Maley,
- Shannon L. Puhalla,
- Fanny Piette,
- Katie Quinn,
- Kyle Chang,
- Rebecca J. Nagy,
- Carmen J. Allegra,
- Kelly Vehec,
- Norman Wolmark,
- Peter C. Lucas,
- Ashok Srinivasan,
- Katherine L. Pogue-Geile
Affiliations
- Samuel A. Jacobs
- NSABP Foundation
- Ying Wang
- NSABP Foundation
- Jame Abraham
- NSABP Foundation
- Huichen Feng
- NSABP Foundation
- Alberto J. Montero
- NSABP Foundation
- Corey Lipchik
- NSABP Foundation
- Melanie Finnigan
- NSABP Foundation
- Rachel C. Jankowitz
- NSABP Foundation
- Mohamad A. Salkeni
- NSABP Foundation
- Sai K. Maley
- NSABP Foundation
- Shannon L. Puhalla
- NSABP Foundation
- Fanny Piette
- International Drug Development Institute
- Katie Quinn
- Guardant Health
- Kyle Chang
- Guardant Health
- Rebecca J. Nagy
- Guardant Health
- Carmen J. Allegra
- NSABP Foundation
- Kelly Vehec
- NSABP Foundation
- Norman Wolmark
- NSABP Foundation
- Peter C. Lucas
- NSABP Foundation
- Ashok Srinivasan
- NSABP Foundation
- Katherine L. Pogue-Geile
- NSABP Foundation
- DOI
- https://doi.org/10.1186/s13058-024-01833-6
- Journal volume & issue
-
Vol. 26,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
